Abstract
Unresectable LAPC has a poor prognosis. Current standard-of-care (SoC) is limited to chemotherapy or chemo-radiotherapy. Brachytherapy using a device containing beta-radiation-emitting Phosphorous-32 (P-32) microparticles is implanted directly into pancreatic tumours via endoscopic-ultrasound (EUS) guidance. We report a post-hoc analysis of resected vs. non-resected cohorts in PanCO, a single-arm, multi-centre, pilot study of P-32 microparticles with SoC chemotherapy in patients with unresectable LAPC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
